Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Great British Bake Off star Candice Brown rushed to hospital after "massive" asthma attackon July 4, 2021 at 1:17 pm
The Great British Bake Off star Candice Brown has revealed she was rushed to hospital after having a "massive, prolonged" asthma attack. Candice, who won the 2016 series, went into hospital after she ...
- Only Four in 10 With Severe Asthma See Specialiston July 2, 2021 at 8:44 am
Specialist care for severe asthma is underutilized, with fewer than four in 10 patients with severe asthma seeking care, according to a study published online June 17 in the Journal of Allergy and ...
- Contributor: To Address Uncontrolled Asthma, Understand the Right Treatments for the Right Patientson July 2, 2021 at 5:15 am
With continued innovations in asthma treatments offering new, improved options for patients, health care providers are more prepared than ever to address uncontrolled asthma head-on.
- Activists breathe easier as Springfield drops down list of ‘asthma capitals’on July 1, 2021 at 2:23 pm
I think it has a lot to do with the great work being done in the valley," said Sarita Hudson, of the Pioneer Valley Asthma Coalition. "It’s happening with health care and housing, working on different ...
- Can the COVID-19 vaccine make asthma symptoms worse?on June 29, 2021 at 6:00 pm
There is no evidence that asthma makes the COVID-19 vaccine more dangerous or that the vaccine worsens asthma symptoms. Learn more.
- Prenatal exposure to ultra-fine particles increases a child’s risk of asthma, study findson June 23, 2021 at 1:30 am
Ultra-fine particles aren’t regulated by the EPA — and their minuscule size amplifies their danger, said the study's lead author.
- Many Americans with severe asthma don't see a specialist to manage their conditionon June 22, 2021 at 9:06 am
Severe asthma can lead to hospitalization, respiratory failure and even death, but despite the high risks, many Americans with this condition are treated by their primary care doctor and not a ...
- More than half of people with asthma aren't seeing a specialiston June 22, 2021 at 7:30 am
Among Americans with severe asthma, less than half see a specialist to manage their condition, new research shows.
- Millions with asthma must get priority Covid booster jabs to lower risk of death, charity sayson June 21, 2021 at 8:35 pm
MILLIONS of Brits suffering with asthma should be given priority booking when it comes to Covid booster jabs, a charity has warned. Despite being eligible, almost half of Brits with asthma have ...
via Bing News